Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice.
Muhammed A SaadNoha M EissaMohammed Abdallah AhmedAliaa Nabil ElMeshadGötz LaibleAhmed S AttiaMedhat A Al-GhobashyRania M AbdelsalamMuhammad Y Al-ShorbagyPublished in: International journal of nanomedicine (2022)
Nano-rhMBP-RTX treated group ameliorated the adverse effects induced in the EAE model. The effectiveness of this formulation was demonstrated by the normalization of EAE-induced behavioral changes and aberrant levels of specific biochemical markers as well as reduced damage of hippocampal tissues and retaining higher levels of myelination.